HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Safety and efficacy of long-term low-dose clozapine aftercare treatment in a patient with learning difficulties who suffered from neuroleptic malignant syndrome.

AbstractINTRODUCTION:
Antipsychotic medication continues to be an essential component in the treatment of schizophrenia. Neuroleptic malignant syndrome (NMS) is one of the most serious complications of neuroleptic treatment and the optimal therapeutic aftercare regimen for patients is unclear. Also, it is not clear if low-dose neuroleptic maintenance in such patients is safe and efficient enough over time.
METHOD:
We present a case of a 56-year-old woman suffering from schizoaffective disorder, who was successfully treated with a low dosage of clozapine for 6.5 years following a NMS episode.
RESULT:
To the best of our knowledge this is the first report of such a long-term beneficial use of low-dose clozapine in a patient who previously underwent such a serious complication.
CONCLUSION:
Large-scale studies are needed to substantiate this observation. (Int J Psych Clin Pract 2002; 6: 121-123).
AuthorsIlya Reznik, Baruch Spivak, Rima Melman, Moshe Kotler, Abraham Weizman, Roberto Mester
JournalInternational journal of psychiatry in clinical practice (Int J Psychiatry Clin Pract) Vol. 6 Issue 2 Pg. 121-3 ( 2002) ISSN: 1365-1501 [Print] England
PMID24931940 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: